AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure

Christophe Beauloye1, Luc Bertrand, Sandrine Horman

  • 1Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardio-Vasculaire, Université catholique de Louvain, Brussels, Belgium.

Cardiovascular Research
|February 3, 2011
PubMed

Insights

Heart failure involves a chronic energy deficit in the heart. AMP-activated protein kinase (AMPK) may be a therapeutic target, regulating cellular energy and potentially protecting the heart.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Molecular Biology

Background:

  • Heart failure is characterized by progressive cardiac dysfunction and a chronic energy deficit.
  • Metabolic disturbances significantly contribute to the transition from compensated hypertrophy to decompensated heart failure.
  • Cellular energy sensing mechanisms, like AMP-activated protein kinase (AMPK), are implicated in heart failure pathogenesis.

Purpose of the Study:

  • To review the current understanding of the chronic energy deficit in heart failure.
  • To explore the role of AMPK in cellular energy homeostasis and its non-metabolic functions.
  • To discuss the potential cardioprotective effects of AMPK in cardiac hypertrophy and heart failure.

Main Methods:

  • Literature review of studies on cardiac energy metabolism.
  • Analysis of research on AMP-activated protein kinase (AMPK) signaling pathways.
  • Synthesis of data regarding AMPK's role in cardiac hypertrophy and heart failure.

Main Results:

  • Failing hearts exhibit a significant chronic energy deficit.
  • AMPK activation influences cellular metabolism and energy balance.
  • AMPK has both energetic and non-metabolic effects relevant to cardiac health.

Conclusions:

  • AMPK plays a crucial role in maintaining energy homeostasis within the heart.
  • Targeting AMPK may offer a therapeutic strategy for heart failure.
  • Further research is needed to elucidate the balance between AMPK's energetic and non-metabolic actions in cardioprotection.

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...